source
- Novo to pay Hengrui up to $2.6 billion for rights to weekly obesity pill HRS-1596Novo announced a deal with China-based Hengrui Pharma, paying $300 million up front for rights to HRS-1596, a once‑weekly obesity pill. The agreement could rise to $2.6 billion if the candidate me…
- Roche drops anti-myostatin obesity drug after mid-stage trial shows limited weight lossRoche announced it will stop development of its anti-myostatin obesity candidate emugrobart after an interim analysis of the Phase 2 GYMINDA trial showed it is unlikely to produce meaningful weight…